European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy OptionsBusiness Wire • 08/19/21
Rand Paul reveals his wife invested in remdesivir parent company Gilead Sciences at the beginning of the pandemicMarket Watch • 08/12/21
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for CancerBusiness Wire • 08/05/21
BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MarylandBusiness Wire • 08/04/21
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match ProgramBusiness Wire • 08/03/21
Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades24/7 Wall Street • 07/30/21
Gilead Sciences Exceeds Expectations As Remdesivir Success Cushions Slump In HIV FranchiseBenzinga • 07/30/21
Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21